Phase I clinical evaluation of a new iron oxide MR contrast agent.
The safety and magnetic resonance (MR) imaging potential of BMS 180549, a new superparamagnetic iron oxide contrast agent, were evaluated in a phase I, open-label, placebo-controlled study involving 41 healthy subjects. No clinically significant postdose changes in physical examination findings, vital signs, or electrocardiogram results were reported for any of the subjects evaluated. No clinically significant changes in clinical laboratory values were noted by the investigators. Fourteen adverse events considered not serious and considered possibly or definitely related to the drug were reported, three of which required minor treatment. Relaxation time measurements in plasma samples showed a strong, dose-dependent, and persistent decrease in T1 and T2 values. Significant changes in MR signal intensity of the blood pool and well-perfused organs (liver and spleen) were noted on both T1- and T2-weighted images. Changes in signal intensity of cervical lymph nodes were also observed at the higher doses and late postdose imaging times.
McLachlan
S J
SJ
Squibb Diagnostics, Plainsboro, NJ 08536.
Morris
M R
MR
Lucas
M A
MA
Fisco
R A
RA
Eakins
M N
MN
Fowler
D R
DR
Scheetz
R B
RB
Olukotun
A Y
AY
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003287:Contrast Media / Q000009:adverse effects; D003911:Dextrans; D004305:Dose-Response Relationship, Drug; D052203:Ferrosoferric Oxide; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007501:Iron / Q000009:adverse effects / Q000097:blood; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008297:Male; D010087:Oxides / Q000009:adverse effects
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide